Cannabinoids Show Promise for Slowing Huntington's Disease Progression in Lab Studies | Research

The takeaway

Preclinical research demonstrated that cannabinoids, particularly the combination of THC and CBD found in Sativex, showed anti-inflammatory and neuroprotective properties relevant to Huntington's disease.

Read this if you are affected by Huntington's disease and want to understand the research on cannabinoid-based treatments.

A clinical trial of Sativex for HD was planned at publication time

What the researchers found

The review examined the potential of cannabinoids to treat Huntington's disease (HD), a genetic neurodegenerative condition affecting primarily the striatum and cortex. While cannabinoids were initially studied for their ability to suppress the involuntary movements (chorea) characteristic of HD, the more promising avenue was disease modification.

Preclinical studies using various HD models showed that cannabinoid agonists, including the phytocannabinoids in Sativex (THC and CBD), had anti-inflammatory, neuroprotective, and neuroregenerative properties. The authors reported being close to initiating a clinical trial of Sativex as a disease-modifying agent in HD patients.

Why it matters

Huntington's disease has no disease-modifying treatment. Current therapies only manage symptoms. If cannabinoids can slow the neurodegeneration that drives HD progression, it would represent a major therapeutic advance for a condition that currently has no way to alter its devastating course.

The numbers in context

HD is caused by excess CAG repeats in the huntingtin gene. Sativex contains a 1:1 THC/CBD ratio. Three cannabinoid medicines were already approved for other conditions. Multiple experimental HD models were used to demonstrate neuroprotective effects.

How the study worked

Review of preclinical evidence from various experimental models of Huntington's disease, including assessment of different cannabinoid agonist types. Also reviewed approved cannabinoid medicines (Cesamet, Marinol, Sativex) and their potential applicability to HD.

What this study cannot tell us

All disease-modifying evidence came from animal and cell models. The history of neurodegenerative disease research is filled with treatments that showed preclinical promise but failed in human trials. The planned Sativex trial had not yet begun at the time of publication.

How to read the evidence

Review of preclinical evidence only; no human clinical data for HD application at the time.

When this study was published

Published in 2012. Subsequent research has continued to investigate cannabinoids in Huntington's disease with mixed clinical trial results.

The bigger picture

This review positioned cannabinoids at the intersection of symptom management and disease modification in neurodegeneration. The neuroprotective and anti-inflammatory properties documented across HD models align with similar findings in other neurodegenerative conditions, suggesting cannabinoids could have broad neuroprotective potential.

Questions still open

Did the planned Sativex clinical trial in HD patients proceed, and what were the results? Can cannabinoids cross the blood-brain barrier in sufficient quantities for neuroprotection? Would earlier treatment (before symptom onset) be more effective?

Common questions

What is Huntington's disease?

Huntington's disease is a genetic condition caused by a mutation in the huntingtin gene. It leads to progressive degeneration of nerve cells primarily in the striatum and cortex, causing involuntary movements (chorea), cognitive decline, and psychiatric symptoms. There is currently no treatment that can slow or stop the disease.

How might cannabinoids help with Huntington's disease?

Preclinical studies showed cannabinoids have anti-inflammatory, neuroprotective, and potentially neuroregenerative properties. In HD models, they reduced the nerve cell damage that drives disease progression. The THC/CBD combination in Sativex was identified as particularly promising because it combines multiple beneficial mechanisms.

Read the original research

Cannabinoids: novel medicines for the treatment of Huntington's disease.

Recent patents on CNS drug discovery, 7(1), 41-8

View on PubMed ↗

Citation

Sagredo, Onintza; Pazos, M Ruth; Valdeolivas, Sara; Fernandez-Ruiz, Javier. (2012). Cannabinoids: novel medicines for the treatment of Huntington's disease.. Recent patents on CNS drug discovery, 7(1), 41-8.